Cannabis and Security Clearances: What the Federal Government Actually Checks
Policy / Culture
2023 Shift
Past cannabis use no longer triggers automatic security clearance denial after 2023 DNI guidance, but current use remains incompatible with holding a clearance at any level.
Director of National Intelligence, Adjudicative Guidance, 2023
Director of National Intelligence, Adjudicative Guidance, 2023
View as imageSecurity clearances are gatekeepers for some of the most consequential careers in the United States. Roughly 4 million Americans hold active security clearances, and millions more work in positions that could require one. For anyone in this population, cannabis presents a specific and sometimes misunderstood challenge. The rules are federal, the evaluation is individual, and the difference between past use that gets mitigated and use that sinks your clearance often comes down to details that most applicants do not fully understand.
The reality of how cannabis use affects security clearances is more nuanced than the binary "any use means denial" narrative that circulates in many clearance-related forums. But it is also more restrictive than what people accustomed to state-level legalization might expect.
Key Takeaways
- Past cannabis use doesn't automatically disqualify you from getting a federal security clearance, but recent, frequent, or ongoing use makes denial or revocation much more likely
- The SF-86 questionnaire asks about drug use in the past seven years, and lying on it does far more damage than the cannabis use itself — because dishonesty raises doubts about your trustworthiness
- The Director of National Intelligence issued 2023 guidance telling adjudicators not to auto-reject applicants for past use in legal states, which signals a shift toward looking at the whole person instead of applying zero-tolerance rules
- Using cannabis right now is still incompatible with holding a clearance at any level, because it remains Schedule I under federal law and clearance holders have to demonstrate federal law compliance
- Investigators look at cannabis under Guideline H (Drug Involvement and Substance Misuse) and weigh factors like how recently you used, how often, the circumstances, and whether you've stopped
- Different agencies handle it differently in practice — intelligence agencies like the CIA and NSA have historically been stricter than civilian agencies like the Department of Energy or State Department
How the Clearance Investigation Works
Security Clearances & Cannabis: What Adjudicators Weigh
Security clearance investigations are conducted by the Defense Counterintelligence and Security Agency for most DOD and federal civilian clearances, with certain intelligence community agencies conducting their own investigations.
The process begins with the applicant completing Standard Form 86, the Questionnaire for National Security Positions. This 127-page form asks detailed questions about your personal history, finances, foreign contacts, employment history, and substance use. The drug use section, which falls under Section 23, asks whether you have illegally used any controlled substance in the last seven years.
Cannabis is a controlled substance under federal law regardless of state legality. Using cannabis in a state where it is legal is still illegal use under the federal framework that governs security clearances. This means the SF-86 drug use question applies to all cannabis use, even recreational purchases from licensed dispensaries in fully legal states.
After the form is submitted, an investigator conducts a background investigation that may include interviews with the applicant, listed references, neighbors, coworkers, and others. The depth of the investigation depends on the clearance level. Confidential and Secret clearances involve a National Agency Check with Law and Credit, while Top Secret and Sensitive Compartmented Information clearances require a more extensive Single Scope Background Investigation.
The completed investigation is then reviewed by an adjudicator who evaluates the applicant against the 13 adjudicative guidelines outlined in Security Executive Agent Directive 4. Drug involvement falls under Guideline H.
What Guideline H Actually Evaluates
Guideline H, Drug Involvement and Substance Misuse, is the primary framework for evaluating cannabis use in clearance decisions. The guideline identifies several conditions that can raise security concerns.
Disqualifying conditions include any substance misuse, testing positive for illegal drug use, illegal drug possession, failure to clearly and convincingly commit to discontinue drug involvement, and failure to complete a prescribed drug treatment program.
Mitigating conditions include behavior that happened so long ago or under such circumstances that it is unlikely to recur, a demonstrated intent not to abuse drugs in the future supported by evidence such as disassociation from drug-using contacts, changing the environment, a signed statement of intent with automatic revocation of clearance for any future violation, or completion of a treatment program.
The key to understanding Guideline H is that it is not a bright-line rule. It is a balancing test. The adjudicator weighs the disqualifying conditions against the mitigating conditions in the context of the whole person. This is where the details of your specific situation matter enormously.
The Honesty Factor: Why Lying Is Worse Than Using
This point cannot be overstated: dishonesty on the SF-86 or during the investigation interview is almost always more damaging to your clearance than the underlying cannabis use would have been.
The security clearance process is fundamentally about trust. The government is evaluating whether you can be trusted with classified information. Someone who lies on a government form to conceal a minor drug history has just demonstrated exactly the kind of vulnerability to coercion and deception that the clearance process is designed to detect.
Falsification on the SF-86 can also constitute a federal crime under 18 U.S.C. 1001, which criminalizes materially false statements to federal agencies. While prosecutions for SF-86 falsification are relatively rare, the possibility exists and is sometimes referenced during investigations.
Adjudicators regularly grant clearances to people who honestly disclose past cannabis use. They rarely grant clearances to people caught lying about it. If your cannabis use is discovered through other means, such as references who mention it during investigator interviews, the falsification becomes a Guideline E (Personal Conduct) issue on top of the Guideline H drug involvement, and the combination is significantly harder to mitigate.
The 2023 DNI Guidance: A Meaningful Shift
In 2023, the Director of National Intelligence issued updated guidance specifically addressing how adjudicators should evaluate cannabis use by clearance applicants. This memo represented the most significant federal shift on cannabis and clearances in decades.
The guidance instructed adjudicators that past cannabis use in a jurisdiction where it was legal should not be treated as automatically disqualifying. It directed adjudicators to apply the whole-person concept and consider the totality of circumstances, including the legality of the use under state law, the recency and frequency of use, and any evidence of changed behavior.
This guidance did not make cannabis use acceptable for current clearance holders. It did not change the federal legal status of cannabis. But it formally acknowledged the reality that a large percentage of the clearance-eligible workforce has used cannabis at some point, particularly younger applicants, and that rigid disqualification for any past use was both impractical and inconsistent with the whole-person evaluation framework.
The practical effect has been meaningful. Adjudicators now have explicit authorization to apply discretion to past cannabis use, and anecdotal reporting from security clearance attorneys suggests that past use is being mitigated more frequently than before the guidance was issued.
Current Use Versus Past Use: The Critical Distinction
The single most important factor in how cannabis use affects your clearance is whether the use is in the past or the present.
Past use that has ceased is mitigable, especially when accompanied by a clear passage of time, a change in circumstances, and a credible commitment to future abstinence. An applicant who used cannabis experimentally in college five years ago, stopped, and now lives in a professional environment where cannabis is not part of their life is in a strong position. The farther in the past the use occurred and the less frequent it was, the more easily it is mitigated.
Current or recent use is a fundamentally different situation. An applicant who reports using cannabis last month, or who states they intend to continue using, is unlikely to receive a clearance. Current use demonstrates ongoing willingness to violate federal law, which is directly at odds with the trustworthiness evaluation. The adjudicator cannot mitigate conduct that is still occurring.
The definition of "recent" is not fixed and depends on context. As a general guideline, most security clearance attorneys recommend at least 12 months of documented abstinence before applying for a clearance, with longer periods recommended for applicants with heavier prior use patterns.
Polygraph Examinations and Cannabis
For clearances that require a polygraph examination, typically Top Secret/SCI positions and intelligence community roles, cannabis use receives additional scrutiny.
The polygraph process involves direct questioning about drug use, and the format is designed to detect deception. An applicant who disclosed past cannabis use on the SF-86 will be asked about it during the polygraph. An applicant who did not disclose it may face questions designed to surface concealed drug history.
The polygraph is not infallible, and its reliability is debated in the scientific community. However, within the clearance process, it functions as an additional layer of inquiry. Applicants sometimes disclose additional cannabis use during the polygraph that they did not include on the SF-86, either because they forgot or because the pressure of the examination prompted fuller disclosure. This creates the falsification problem discussed earlier, even when the omission was unintentional.
The practical advice for anyone facing a clearance polygraph is consistent with the general advice: be completely honest about cannabis use from the start. Disclosing past use on the SF-86 and then confirming that same history during the polygraph is straightforward. Having inconsistencies between the form and the polygraph is problematic.
Agency-Specific Variations
While the adjudicative guidelines are theoretically uniform across agencies, practical enforcement varies.
Intelligence community agencies including the CIA, NSA, and DIA have historically applied the strictest standards for drug involvement. These agencies conduct their own investigations and polygraphs and have historically applied a conservative interpretation of Guideline H. The CIA specifically has a policy requiring at least 12 months of abstinence from any illegal drug use prior to applying, and some internal positions require longer periods.
DOD civilian and contractor positions generally follow the DCSA investigation and adjudication framework. Past cannabis use is routinely mitigated for these positions when it is disclosed honestly, occurred in the past, and the applicant demonstrates changed behavior. These represent the majority of security clearance positions.
Department of Energy Q and L clearances follow a similar framework to DOD clearances but are adjudicated by DOE. The Department of Energy has historically been somewhat pragmatic about past cannabis use, particularly for scientific positions where the applicant pool skews younger and past experimental use is common.
Law enforcement agencies including the FBI, DEA, and Secret Service have their own drug use policies that interact with but are separate from the clearance adjudication process. The FBI, for example, has a policy requiring no cannabis use within three years of application, independent of the clearance evaluation.
What to Do If You Have Used Cannabis
If you have used cannabis and need to obtain or maintain a security clearance, the path forward involves several practical steps.
Stop using cannabis immediately. Every day of continued use extends the timeline for mitigation. There is no amount of cannabis use that is compatible with holding a current security clearance.
Be completely honest on the SF-86 and during all investigator interactions. Disclose the full scope of your use, including approximate dates, frequency, and the circumstances. Partial disclosure is worse than full disclosure.
Document your abstinence and changed behavior. Disassociate from environments and contacts associated with cannabis use. If applicable, complete any substance abuse evaluation or treatment recommended. Consider a signed statement of intent to abstain with automatic revocation of clearance for future use, which is specifically listed as a mitigating condition under Guideline H.
Consult a security clearance attorney, particularly if your use was recent, frequent, or if you are applying for a Top Secret or SCI clearance. These attorneys understand the adjudicative process and can help you present your history in the strongest possible light while remaining fully honest.
The bottom line is that cannabis use is a manageable clearance issue for most applicants if handled correctly. Past use, honestly disclosed, with demonstrated changed behavior, is routinely mitigated. Current use or dishonesty about past use will likely cost you the clearance.
This article is for informational purposes only and does not constitute legal advice. Security clearance policies and adjudicative standards evolve over time. Consult a security clearance attorney for guidance specific to your situation.
The Bottom Line
Security clearance and cannabis covering SF-86, adjudication, agency variations, and practical guidance. Investigation process: SF-86 Section 23 asks about drug use in past 7 years; cannabis = illegal under federal framework regardless of state law; DCSA conducts most investigations; clearance levels determine investigation depth (NAC for Secret, SSBI for TS/SCI). Guideline H evaluation: disqualifying conditions (any misuse, positive test, failure to commit to discontinuation); mitigating conditions (passage of time, changed circumstances, signed statement of intent with automatic revocation, treatment completion); balancing test, not bright-line rule. Honesty critical: lying on SF-86 worse than use itself — demonstrates vulnerability to coercion, potential 18 U.S.C. 1001 violation, triggers Guideline E (Personal Conduct) on top of Guideline H; adjudicators routinely grant clearances with honest disclosure, rarely with detected dishonesty. 2023 DNI guidance: instructed adjudicators not to automatically disqualify for past legal-state use; directed whole-person evaluation; did not change current use prohibition; meaningful practical impact on adjudication rates. Past vs current use: past use = mitigable with time/changed behavior/abstinence commitment; current/recent use = likely denial; most attorneys recommend 12+ months documented abstinence. Polygraph: additional scrutiny for TS/SCI; inconsistencies between SF-86 and polygraph disclosure = falsification problem. Agency variations: CIA/NSA strictest (CIA requires 12mo+ abstinence); DOD civilian/contractor = majority of positions, routinely mitigated; DOE pragmatic especially for scientific positions; FBI requires 3yr no-use policy.
Frequently Asked Questions
Sources & References
- 1RTHC-06444·Feinberg, Steven D et al. (2025). “Occupational medicine guideline says cannabis is not recommended for common workplace injuries and conditions.” Journal of occupational and environmental medicine.Study breakdown →PubMed →↩
- 2RTHC-07874·Vikingsson, Svante et al. (2025). “Legal CBD Products With Trace THC Can Cause Positive Drug Tests in Oral Fluid.” Journal of analytical toxicology.Study breakdown →PubMed →↩
- 3RTHC-07964·Wolinsky, David et al. (2025). “How CBD and Low-Dose THC From Hemp Products Affect Drug Tests and the Body.” Journal of analytical toxicology.Study breakdown →PubMed →↩
- 4RTHC-05832·Yang, Kevin H et al. (2024). “Cannabis Use and Cannabis Use Disorder Linked to More Missed Work Days in National Survey.” American journal of preventive medicine.Study breakdown →PubMed →↩
- 5RTHC-04218·Sholler, Dennis J et al. (2022). “Oral cannabis produced higher urine drug test concentrations than vaporized cannabis.” Journal of analytical toxicology.Study breakdown →PubMed →↩
- 6RTHC-04024·MacCallum, Caroline A et al. (2022). “A Clinical Framework for Assessing Cannabis Impairment Risk in Patients.” Frontiers in psychiatry.Study breakdown →PubMed →↩
- 7RTHC-01228·Molnar, Anna et al. (2016). “How Sativex Complicates Drug Testing: A Review of THC Detection Methods Across Blood, Urine, Saliva, and Hair.” Bioanalysis.Study breakdown →PubMed →↩
- 8RTHC-07602·Schumacher, Joseph E et al. (2025). “Cannabis Was the Most Common Drug Found in First-Time Jail Arrestees.” Addiction science & clinical practice.Study breakdown →PubMed →↩
Research Behind This Article
Showing the 8 most relevant studies from our research database.
Cannabis Use, Use Disorder, and Workplace Absenteeism in the U.S., 2021-2022.
Yang, Kevin H · 2024
Past-month cannabis use was associated with more missed work days due to illness and more skipped work days compared to no lifetime use.
Cannabis.
Feinberg, Steven D · 2025
Some evidence for MS spasticity, but no quality evidence for back pain, radiculopathy, neuropathic pain, or other common work-related pain.
The Acute and Chronic Pharmacokinetic Oral Fluid Profile of Oral Cannabidiol (CBD) With and Without Low Doses of Delta-9-Tetrahydrocannabinol (Δ9-THC) in Healthy Human Volunteers.
Vikingsson, Svante · 2025
After taking 100 mg CBD with just 0.5 mg THC (well within legal hemp limits), 1 in 10 participants tested positive for THC in oral fluid.
The Acute and Chronic Pharmacokinetics and Pharmacodynamics of Oral Cannabidiol (CBD) With and Without Low Doses of Delta-9-Tetrahydrocannabinol (Δ9-THC).
Wolinsky, David · 2025
Even small amounts of THC in legal hemp CBD products (0.5-3.7 mg) could lead to positive drug tests after repeated use, with pharmacokinetic and pharmacodynamic effects varying by dose..
Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users.
Sholler, Dennis J · 2022
Using federal workplace drug-testing criteria (50 ng/mL screening, 15 ng/mL confirmation), urine specimens tested positive for THC-COOH in 97.6% of oral cannabis sessions versus 59.5% of vaporized sessions at active THC doses..
Workplace and non-workplace cannabis use and the risk of workplace injury: Findings from a longitudinal study of Canadian workers.
Carnide, Nancy · 2023
Among 2,745 Canadian workers followed from 2018-2020, workplace cannabis use (before or at work) was associated with a nearly two-fold increased risk of workplace injury (RR 1.97, 95% CI 1.32-2.93).
Workplace Drug Testing-Prevalence of Positive Test Results, Most Common Substances, and Importance of Medical Review.
Helander, Anders · 2025
This analysis of 23,900 workplace drug test results from Sweden provides a snapshot of substance use among employed people.
Cross-sectional analysis of cannabis use at work in the USA: differences by occupational risk level and state-level cannabis laws.
Kucera, Ava · 2025
Workplace use highest in recreational states (8.5%) vs.